Cardiovascular Psychiatry and Neurology

Cardiovascular Psychiatry and Neurology / 2009 / Article
Special Issue

Hypotheses on Mechanisms Linking Cardiovascular and Psychiatric/Neurological Disorders

View this Special Issue

Hypothesis | Open Access

Volume 2009 |Article ID 475108 |

Charles D. Nichols, "Serotonin 5- Receptor Function as a Contributing Factor to Both Neuropsychiatric and Cardiovascular Diseases", Cardiovascular Psychiatry and Neurology, vol. 2009, Article ID 475108, 8 pages, 2009.

Serotonin 5- H T 2 A Receptor Function as a Contributing Factor to Both Neuropsychiatric and Cardiovascular Diseases

Academic Editor: Hari Manev
Received01 Jun 2009
Revised07 Aug 2009
Accepted14 Aug 2009
Published13 Oct 2009


There are high levels of comorbidity between neuropsychiatric and cardiovascular disorders. A key molecule central to both cognitive and cardiovascular function is the molecule serotonin. In the brain, serotonin modulates neuronal activity and is actively involved in mediating many cognitive functions and behaviors. In the periphery, serotonin is involved in vasoconstriction, inflammation, and cell growth, among other processes. It is hypothesized that one component of the serotonin system, the receptor, is a common and contributing factor underlying aspects of the comorbidity between neuropsychiatric and cardiovascular disorders. Within the brain this receptor participates in processes such as cognition and working memory, been implicated in effective disorders such as schizophrenia, and mediate the primary effects of hallucinogenic drugs. In the periphery, receptors have been linked to vasoconstriction and hypertension, and to inflammatory processes that can lead to atherosclerosis.

Neuropsychiatric disorders have high levels of comorbidity with cardiovascular disease. A recent retrospective study indicates that metabolic syndrome was reported in about 40% of schizophrenic patients, 35% of bipolar patients, and 25% of patients with recurrent depression [1]. Environmental factors, including medications, likely underlie some of the metabolic dysfunction associated with schizophrenia and depression, however, studies in unmedicated drug naïve first episode schizophrenics indicate that a pathological association exists [2]. Significantly, many other studies have also linked metabolic syndrome, cardiovascular disease, and psychiatric disorders [37], and specific aspects of cardiovascular disease like atherosclerosis and hypertension are associated with psychiatric disorders [810]. Patients with schizophrenia have an average reduction in life expectancy of 15 years, largely due to coronary heart disease [11]. Unfortunately, many therapeutics used to treat psychiatric disorders can have significant negative influences on aspects of cardiovascular function and have thus clouded the nature of these links with regard to cause and effect. Antipsychotic medications, as well as therapeutics for other psychiatric disorders, can have dramatic effects on metabolic processes and can induce metabolic syndrome, weight gain, and diabetes, which are all significant risk factors for the development of cardiovascular diseases [1215]. Furthermore, prolongation of the interval between ventricular depolarization and repolarization (QT interval) also has been associated with antipsychotic medications [16]. Overall, metabolic and cardiovascular dysfunction associated with neuropsychiatric disorders, therefore, likely represent a mixture of environmental, medication, and pathological factors.

Whereas the exact biochemical nature of the links between cardiovascular disease and psychiatric disorders remains elusive, it is evident that there is a strong association between these biological processes. The fact that medications used to treat one condition can influence, and even induce, the other condition underscores these associations. With respect to depression, models have been proposed that largely invoke an underlying dysregulation of the HPA axis, which through modulation of factors such as cortisol and CRF influence mood, affect, immunity, and cardiovascular function [6, 17, 18].

Aspects of cardiovascular disease including endothelial dysfunction and atherosclerosis are acutely mediated by inflammatory mechanisms. For example, adipose tissues can release proinflammatory cytokines into the circulation. As more adipose tissues are present in an individual, represented by a higher body mass index, more cytokines can be released. These cytokines, primarily Tumor Necrosis Factor-α (TNF-α) and IL6, can directly induce inflammation in cardiovascular tissues, as well as activate the HPA axis, which in turn can lead to metabolic syndrome. Metabolic syndrome can subsequently lead to oxidative stress and generation of free radicals that together induce further production of proinflammatory cytokines, and the two processes of inflammation and metabolic syndrome can interact synergistically to elevate levels of proinflammatory cytokines and promote further endothelial dysfunction and atherosclerosis [19]. A detailed review of the development and progression of atherosclerosis itself will not be given here, and the reader is referred to other reviews and references therein [20, 21]. A key mediator of the development of atherosclerosis is the cytokine TNF- which, acting through its receptors on the surface of macrophage, endothelial, and smooth muscle cells of the vasculature, induces signal transduction cascades leading to NOS activity, activation of transcription factors such as Nuclear Factor kappa B (NF- B), and production of proinflammatory adhesion molecules and cytokines such as ICAM-1, VCAM-1, and IL6. Together, these processes facilitate macrophage infiltration of the arterial wall, differentiation of macrophages to lipid-accumulating foam cells, and migration of arterial smooth muscle cells to form a fibrous cap, together constituting the atherosclerotic plaque. Severe cases cause significant blockage of the artery, and eventual rupture of the plaque and thrombosis.

Recently, cytokine-mediated inflammation has been implicated in the development and presentation of psychiatric disorders that include depression and psychosis [2224]. In major depression and bipolar disease, increases in TNF- , and other proinflammatory cytokines (e.g., IL6, and other proinflammatory molecules such as ICAM-1 and MCP-1), have been found within the CNS [23, 25]. Although the association of inflammation with depression does not necessarily imply causality, certain symptoms of depression have been shown in both clinical studies and animal models to be alleviated by anti-inflammatory therapeutics [26]. Interestingly, knockout mice lacking TNF-α receptors exhibit antidepressant-like behaviors in several types of assays [27]. Neuroinflammation leading to dysfunction of the adult CNS as well as inflammatory events in utero leading to perturbation of normal synaptic development has been proposed as possible factors contributing to psychiatric disorders [23, 24].

It has long been recognized that 5-hydroxytryptamine (serotonin; 5-HT), and its biosynthetic precursor tryptophan, play an important role in regulating immune functions through non-5-HT receptor interactions involving circulating tryptophan and kynurenine levels [2830]. Individual serotonin receptors, however, are expressed in many immune-related tissues, and interactions at specific receptors are also known to modulate aspects of the immune response and inflammation [3133]. Within the CNS, serotonin and serotonin receptors have been strongly associated with normal function. Certain neuropsychiatric disorders that include depression, bipolar disorder, OCD, anorexia, and schizophrenia have been linked to dysregulation of CNS serotonin [34, 35]. Indeed, therapeutics for these disorders often include inhibition of the serotonin transporter (SERT) with selective serotonin reuptake inhibitor (SSRI) medications, or blockade of specific serotonin receptor subtypes. SSRIs can also show an efficacy in treating aspects of cardiovascular disease associated with depression [36], and have been demonstrated in animal models to have an anti-inflammatory effect [37]. The mechanisms underlying the protective effect of antidepressants are not precisely known, but are predicted by some researchers to involve activation of the pituitary-adrenocortical system via increased central serotonin levels [38], by modulation of cytokine levels in peripheral tissues [39, 40], and by suppression of platelet activation [41]. Furthermore, acute SSRI administration has been shown to have a vasodilatory effect on the coronary artery that may be cardioprotective [42]. Interestingly, TNF-α, as well as certain other cytokines, have been shown to influence both expression and transport activity of the serotonin transporter. In neuronally derived cells and choriocarcinoma cells, TNF-α, INF- , and IL1 increase function [4345], whereas in B lymphocytes, IL4 decreases function [46], and in intestinal epithelial derived Caco-2 cells, TNF-α has been found to decrease both expression and transport activity of SERT [47]. Whereas the nature of the influence of cytokines on SERT function (e.g., facilitation or repression) likely depends on the cytokine and tissue, modulation of synaptic serotonin levels in various brain regions by inflammatory cytokines would certainly be anticipated to have some effect on neuronal function relevant to psychiatric disorders like depression. In summary, there appears to be a strong link between proper functioning and regulation of the serotonin system and factors underlying cardiovascular disease and neuropsychiatric disorders.

We hypothesize that a particular aspect of the serotonin system, the 5-HT2A receptor, is a common and contributing factor underlying aspects of normal cardiovascular and CNS function, and that dysfunction of this receptor results in certain characteristics of cardiovascular and neuropsychiatric disorders. There are seven families of serotonin receptors comprised of fourteen distinct subtypes [48]. With the exception of the 5-HT3 receptor, which is a ligand-gated ion channel, all are seven transmembrane-spanning G-protein-coupled receptors. Of all the serotonin receptors, the 5-HT2A receptor has been the one most closely linked to complex behaviors and neuropsychiatric disorders. The 5-HT2A receptor is highly expressed within the frontal cortex, with lower expression levels throughout the brain [48]. There has been extensive research performed to establish the role of 5-HT2A receptors within the brain, where they have been shown to participate in processes such as cognition and working memory [49], mediate the primary effects of hallucinogenic drugs [50], and been implicated in mechanisms underlying schizophrenia [51, 52]. Furthermore, abnormal expression of 5-HT2A receptors has also been linked to depression. For example, some studies have shown that receptor protein expression is increased in certain cortical areas of patients with major depression [53, 54], as well as suicide victims [55, 56]. 5-HT2A receptor expression decreases, however, have been found in brain limbic regions of patients with major depressive disorder [57].

Significantly, 5-HT2A receptors are found outside the CNS in many diverse tissues, including those related to cardiovascular function. Their role in the periphery, however, is less clear. Also, 5-HT2A receptor mRNA is expressed within vascular smooth muscle and endothelial cells, and cardiomyocytes, where the receptors are believed to mediate aspects of vasoconstriction and cellular proliferation [5860]. Not only can 5-HT2A receptor activity modulate cardiovascular function in the periphery, but it has been found to act centrally: activation of 5-HT2A receptors in the nucleus tractus solitarius of the brain dramatically lowers both blood pressure and heart rate [61].

Recently, we have found that selective activation of 5-HT2A receptors in primary aortic smooth muscle inhibits TNF-α-mediated inflammatory markers with extraordinary potency. With an IC50 value of about 10 picomolar, 5-HT2A receptor activation with the drug (R)-DOI inhibits NOS activity, the activation and nuclear translocation of the p65 subunit of NF- B, as well as the production of mRNA for the proinflammatory cell adhesion proteins ICAM-1 and VCAM-1, and mRNA for the cytokine IL6 [33]. Other chemically diverse molecules that activate 5-HT2A receptors, including the hallucinogen lysergic acid diethylamide (LSD), also have potent anti-inflammatory effects on aortic smooth muscle in vitro [33], indicating that this is a property of 5-HT2A receptor activation and not specific to a particular drug. Significantly, we have found potent anti-inflammatory effects in primary aortic endothelial cells as well as macrophages (unpublished data). TNF-α signaling in these three cell types, aortic smooth muscle, endothelial, and macrophage, is believed to be a major contributing factor to the inflammatory processes underlying the development and progression of atherosclerosis. As such, drugs acting at 5-HT2A receptors, like (R)-DOI, may represent a novel class of superpotent small molecule inhibitors of TNF-α pathway signaling with therapeutic potential for treating not only atherosclerosis but also other inflammatory conditions involving TNF-α, that are more then 100-fold more potent than the more potent steroidal anti-inflammatories currently on the market. Importantly, we have also found potent anti-inflammatory effects of 5-HT2A receptor activation in CNS-related cell culture systems, including C6 glioma, and SH-SY5Y neuroblastoma cells (unpublished data), indicating that the role of 5-HT2A receptors in mediating anti-inflammatory pathways is not limited to cardiovascular tissues, but is likely relevant in the CNS.

As mentioned previously, drugs that interact with or influence 5-HT2A receptor function can dramatically affect aspects of cardiovascular function. Some, including atypical antipsychotic, medications have a negative influence, while others, including ketanserin and certain antidepressants, are reported to have a beneficial cardiovascular effect. How do these effects fit within the framework of our hypothesis?

Ketanserin has been effective in the clinic as an antihypertensive agent as well as an antiarrhythmic. It can also sometimes induce proarrhythmias, and was withdrawn from the market largely for this reason. Recent reports suggest that the antiarrhythmic effects of ketanserin may be due to direct interactions with certain potassium channels, including the HERG channel, and not to blockade of the 5-HT2A receptor per se [6264]. With regards to ketanserin’s use as an antihypertensive, the underlying mechanisms are not entirely clear as ketanserin has significant affinity for the alpha-1 adrenergic receptor, and many reports have cited this as the putative antihypertensive therapeutic target rather than antagonism of the 5-HT2A receptor [58, 65, 66]. Nevertheless, many in vitro studies of 5-HT2A receptor antagonists have clearly demonstrated that 5-HT-induced vasoconstriction in isolated vascular tissue preparations is in large part mediated by 5-HT2A receptors [60]. Although blockade of 5-HT2A receptors can potently inhibit serotonin-mediated vasoconstriction in isolated vascular preparations, aside from ketanserin, other 5-HT2A receptor antagonists show little to no antihypertensive effect in vivo [66, 67]. Indeed, newer highly selective 5-HT2A receptor antagonists, like M100907 (volinanserin), ACP-103 (primavanserin), and SR46349B (eplivanserin), are currently in clinical trials as novel therapeutics to treat insomnia [68] and there are no reports in literature describing effects on hypertension, inflammation, or other cardiovascular processes. One report, however, examining the physiological and pharmacokinetics of ACP-103 in a small study comprised of normal human subjects has been published that concluded that there were no significant changes in vital signs or ECG associated with treatment for up to fourteen days [69].

An interesting study recently published detailed the effects of chronic increases in circulating serotonin levels, as opposed to large bolus doses. It was predicted that, as occurs with a bolus dose of serotonin, blood pressure would increase due to the vasoconstrictive effects of increased 5-HT acting at 5-HT2 receptors. It was found that increased circulating 5-HT levels actually significantly decreased blood pressure [70, 71]. The author of this study stated that it was unlikely that direct activation of vasoralaxant 5-HT receptors was responsible for this effect, and that further studies are needed to elucidate underlying mechanisms [70]. If antagonism of 5-HT2A receptors is expected to produce hypotension and affect cardiac rhythmicity, then activation would be anticipated to produce hypertension and potentially affect rhythmicity. This has not been the case. In humans, the 5-HT2A receptor agonist, psilocybin, which also has high affinity for 5-HT1A receptors, produces only mild and transient cardiovascular effects at high doses when administered systemically. Highly hallucinogenic doses (e.g., 30 mg) only produce minor and transient increases in baseline heart rate ( 10 bpm) and blood pressure ( 15%) and do not influence heart function as measured by electrocardiogram [7274]. Lower non-hallucinogenic doses of psilocybin do not produce significant changes in heart rate, blood pressure, or heart function [7274]. Another 5-HT2A receptor agonist dimethyltryptamne (DMT) has been given to humans at highly hallucinogenic doses [75]. In that study, intravenous injection of DMT was found to only elicit minor and very transient increases in heart rate and blood pressure [75]. It should be noted that some of these increase can probably be attributed to psychological stress and anxiety produced by the hallucinogenic effects of psilocybin and DMT at high doses, and not by a direct pharmacological action on blood pressure or heart rate. There have been no studies reported examining the effects of chronic administration of 5-HT2A receptor agonists in mammals. It will be interesting to see in future experiments if chronic administration of these agents affects inflammation-related cardiovascular diseases or other aspects of cardiovascular function. Our data indicate that potential anti-inflammatory effects of agonists like (R)-DOI would be evident at doses far below that necessary to elicit behavioral effects like hallucinations. Interestingly, there are antidepressant-like effects associated with single hallucinogenic doses of psilocybin [73, 76].

Atypical antipsychotic medications like olanzapine, clozapine, and risperidone belong to a newer class of drug that are believed to have a component of their therapeutic effect mediated by antagonism of 5-HT2A receptors [77]. Unlike traditional antipsychotic medications like haloperidol that act primarily as antagonists at dopamine D2 receptors, atypical antipsychotics have some efficacy at treating the negative, or more cognitive, symptoms of schizophrenia, and this may be due to their effects on 5-HT2A receptors. As previously mentioned, pathological associations exist between schizophrenia and metabolic syndrome and cardiovascular disorders, however, the use of atypical antipsychotics is, unfortunately, strongly associated with the development of significant weight gain, metabolic, and cardiovascular disorders [14, 15, 78]. The substantial weight gain associated with atypical antipsychotics is believed to partially involve antagonist or inverse agonist activity of these drugs at 5-HT2C receptors [79]. Indeed, the 5-HT2C knockout mouse is severely obese [80], and agonists of this receptor can produce hypophagia [81]. Although many aspects of metabolic and cardiovascular disorders associated with atypical antipsychotics are likely a direct consequence of weight gain, other aspects may be mediated by blockade of 5-HT2A receptor function. For example, 5-HT2A receptors have been implicated in regulation of glucose homeostasis [82, 83], and antagonism of the 5-HT2A receptor may influence insulin sensitivity [84, 85]. Within the framework of our hypothesis, aberrant 5-HT2A receptor function may contribute to both psychosis and pathological association of metabolic and cardiovascular disorders. This dysfunction could result in hyperacticvity in the CNS, and contribute to psychosis. In the periphery, receptor dysfunction may promote processes leading to metabolic disorder and cardiovascular disease through largely unexplored mechanisms. Whereas blockade of 5-HT2A receptor hyperfunction in the CNS may be therapeutic for treating psychosis, receptor blockade, both in the CNS and periphery, may also interfere with endogenous anti-inflammatory processes and synergistically act with the effects of induced weight gain to produce significant metabolic and cardiovascular disorders.

Another class of medication that affects psychiatric disorders, inflammatory processes, and cardiovascular function is selective serotonin reuptake inhibitor antidepressants (SSRIs). Interestingly, SSRI antidepressant medications have a biphasic effect on serotonin within the brain. Acute treatment leads to decreased serotonin release, and chronic treatment leads to increased release [86, 87]. The acute decrease in 5-HT release results from autoreceptor activation and subsequent inhibition of release and synthesis of serotonin. As these receptors desensitize with chronic SSRI treatment, however, overall 5-HT transmission is facilitated. Chronic treatment with SSRI antidepressants also has been shown to produce significant downregulation and desensitization of 5-HT2A receptors both in vitro and in vivo similar to chronic treatment with atypical antipsychotics [88]. The effects of SSRI induced receptor desensitization and downregulation would be anticipated to mimic the effects of chronic treatment with atypical antipsychotics, and reduce overall 5-HT2A receptor function. Within the framework of our model, these effects would be predicted to produce a deficit in receptor function, and increases in proinflamatory mechanisms potentially leading to cardiovascular disease, metabolic disorders, and neuroinflammation. SSRI antidepressants, however, have been shown to have anti-inflammatory activity and to be cardioprotective when given both acutely and chronically. It is conceivable that the acute anti-inflammatory and cardioprotective effects of SSRI antidepressants are mediated by mechanisms other than manipulation of 5-HT2A receptor function, as discussed previously, and the beneficial effects of chronic treatment may involve enhanced 5-HT tone at 5-HT2A receptors. Although chronic treatment with SSRI antidepressants produces desensitization and downregulation of 5-HT2A receptors, our results demonstrate that 5-HT2A receptors in this state are actually more sensitive to the anti-inflammatory effects of activation by the agonist (R)-DOI by an order of magnitude [33]. Together, the anti-inflammatory and cardioprotective effects of SSRI antidepressants are, therefore, likely a combination of direct modulation of cytokines, central action within the CNS, and modulation of 5-HT2A receptor function, with each component contributing differently as therapy progresses to achieve a steady state.

Here, we propose that deficits in 5-HT2A receptor function underlie at least part of the comorbidity of cardiovascular disease and neuropsychiatric disorders. If 5-HT2A receptor activation normally appears to exert a powerful anti-inflammatory influence on a variety of cells, especially vascular tissues, dysfunction may be anticipated to lead to a repression of anti-inflammatory influences and to the expression of proinflammatory markers, sensitization of the cell to inflammatory stimuli, or both, leading to an increased risk of inflammation and atherosclerosis. Similarly, 5-HT2A receptor dysfunction also may contribute to increased risk of hypertension, and cardiac hypertrophies within the cardiovascular system. Unfortunately, there are few, if any, studies reported in literature examining expression levels of 5-HT2A receptors in diseased cardiovascular related tissues. This simply may be due to the fact that no one has looked. If so, then examination of receptor levels in diseased cardiovascular-related tissues may be a productive avenue of exploration. In rat models of congestive heart failure, there are two reports demonstrating increased levels of 5-HT2A receptor mRNA [59, 89]. It remains to be determined if the increased expression is causative, or a compensatory response to other factors.

Within the CNS, the same receptor dysfunction may result in or contribute to the development of neuropsychiatric disorders including depression, bipolar disease, and psychosis. This dysfunction may either come from alterations in regulation due to promoter polymorphisms or other regulatory mechanisms influencing expression, or polymorphisms or mutations affecting the protein itself that could influence responsiveness and downstream signal transduction pathways. Polymorphisms in the promoter region of the human HTR2A locus have been shown to alter receptor expression levels [90], and these same polymorphisms have been linked to response to antisychotics and certain SSRIs [91, 92], and in some studies positively associated with various CNS conditions including major depression, bipolar disorder, and schizophrenia [9396]. Significantly, positive associations also have been detected for these polymorphisms and symptoms of cardiovascular-related disorders [97]. Polymorphisms within the coding regions of the HTR2A locus have been found in some studies to be positively associated with neuropsychiatric disorders, as well as to rheumatoid arthritis [98], circulating cholesterol levels [99], hypertension [100], myocardial infarction [101], as well as blood pressure and metabolic syndrome [102].

There is significant opportunity for future research to investigate how 5-HT2A receptor function mediates certain aspects of both neuropsychiatric and cardiovascular-related disorders. Greater clarification of the role of receptor antagonists in vivo is needed. This could involve examining the effects of the new highly selective receptor antagonists in rodent models of cardiovascular disease and atherosclerosis, as well as careful examination of clinical trial data for the use of these drugs as sleep aids and continued analysis for the effects of chronic use on cardiovascular-related issues after these therapeutics come to market. Not only could results from these types of studies be informative about the effects of selective receptor blockade on cardiovascular-related diseases but they could also help to address the question of whether or not the negative cardiovascular and metabolic effects of atypical antipsychotics have a significant 5-HT2A receptor-mediated component. If they did, then perhaps long-term therapy with these new highly selective receptor antagonists would produce metabolic and cardiovascular disorders. In our laboratory, we are continuing to study the effects of agonists on inflammation-related cardiovascular processes, and attempting to elucidate the molecular mechanisms underlying their anti-inflammatory effects. An additional resource that would beneficial to explore is the 5-HT2A receptor knockout mouse model. Amazingly, given the widespread expression and importance of the 5-HT2A receptor, the knockout animal appears overtly normal. There are, however, certain behavioral effects associated with loss of this receptor [103, 104]. Interestingly, some observed behaviors are opposite to the effects of receptor antagonists [105], indicating that caution should be exercised in the interpretation of knockout studies using this model. Nevertheless, studies utilizing this mouse in models of cardiovascular-related diseases will likely be of value. A better understanding of the relationship between 5-HT2A receptor function and its roles in both the CNS and cardiovascular system should lead to development of improved therapeutics to treat diseases affecting each of these systems either separately or together.


  1. M. Jakovljević, Ž. Crnčević, D. Ljubičić, D. Babić, R. Topić, and M. Šarić, “Mental disorders and metabolic syndrome: a fatamorgana or warning reality?” Psychiatria Danubina, vol. 19, no. 1-2, pp. 76–86, 2007. View at: Google Scholar
  2. J. M. Meyer and S. M. Stahl, “The metabolic syndrome and schizophrenia,” Acta Psychiatrica Scandinavica, vol. 119, no. 1, pp. 4–14, 2009. View at: Publisher Site | Google Scholar
  3. R. S. McIntyre, J. K. Soczynska, J. Z. Konarski et al., “Should depressive syndromes be reclassified as “metabolic syndrome type II”?” Annals of Clinical Psychiatry, vol. 19, no. 4, pp. 257–264, 2007. View at: Publisher Site | Google Scholar
  4. E. M. Goldbacher and K. A. Matthews, “Are psychological characteristics related to risk of the metabolic syndrome? A review of the literature,” Annals of Behavioral Medicine, vol. 34, no. 3, pp. 240–252, 2007. View at: Publisher Site | Google Scholar
  5. R. O. Gans, “The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms,” Medical Clinics of North America, vol. 90, no. 4, pp. 573–591, 2006. View at: Publisher Site | Google Scholar
  6. R. Ramasubbu, “Insulin resistance: a metabolic link between depressive disorder and atherosclerotic vascular diseases,” Medical Hypotheses, vol. 59, no. 5, pp. 537–551, 2002. View at: Publisher Site | Google Scholar
  7. P. Fusar-Poli, L. de Marco, F. Cavallin, A. Bertorello, M. Nicolasi, and P. Politi, “Lifestyles and cardiovascular risk in individuals with functional psychoses,” Perspectives in Psychiatric Care, vol. 45, no. 2, pp. 87–99, 2009. View at: Publisher Site | Google Scholar
  8. C. A. Shively, D. L. Musselman, and S. L. Willard, “Stress, depression, and coronary artery disease: modeling comorbidity in female primates,” Neuroscience and Biobehavioral Reviews, vol. 33, no. 2, pp. 133–144, 2009. View at: Publisher Site | Google Scholar
  9. E. D. Williams and A. Steptoe, “The role of depression in the etiology of acute coronary syndrome,” Current Psychiatry Reports, vol. 9, no. 6, pp. 486–492, 2007. View at: Publisher Site | Google Scholar
  10. G. E. Plante, “Depression and cardiovascular disease: a reciprocal relationship,” Metabolism, vol. 54, no. 5, supplement 1, pp. 45–48, 2005. View at: Google Scholar
  11. C. H. Hennekens, A. R. Hennekens, D. Hollar, and D. E. Casey, “Schizophrenia and increased risks of cardiovascular disease,” American Heart Journal, vol. 150, no. 6, pp. 1115–1121, 2005. View at: Publisher Site | Google Scholar
  12. J. M. Meyer and C. E. Koro, “The effects of antipsychotic therapy on serum lipids: a comprehensive review,” Schizophrenia Research, vol. 70, no. 1, pp. 1–17, 2004. View at: Publisher Site | Google Scholar
  13. A. Fagiolini, K. N. R. Chengappa, I. Soreca, and J. Chang, “Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden,” CNS Drugs, vol. 22, no. 8, pp. 655–669, 2008. View at: Publisher Site | Google Scholar
  14. R. N. Bergman and M. Ader, “Atypical antipsychotics and glucose homeostasis,” Journal of Clinical Psychiatry, vol. 66, no. 4, pp. 504–514, 2005. View at: Google Scholar
  15. H. Y. Meltzer, M. Davidson, A. H. Glassman, and W. V. Vieweg, “Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment,” Journal of Clinical Psychiatry, vol. 63, supplement 9, pp. 25–29, 2002. View at: Google Scholar
  16. E. Lindström, L. Farde, J. Eberhard, and W. Haverkamp, “QTc interval prolongation and antipsychotic drug treatments: focus on sertindole,” International Journal of Neuropsychopharmacology, vol. 8, no. 4, pp. 615–629, 2005. View at: Publisher Site | Google Scholar
  17. J. Jokinen and P. Nordström, “HPA axis hyperactivity and cardiovascular mortality in mood disorder inpatients,” Journal of Affective Disorders, vol. 116, no. 1-2, pp. 88–92, 2009. View at: Publisher Site | Google Scholar
  18. W. Coryell, J. Fiedorowicz, M. Zimmerman, and E. Young, “HPA-axis hyperactivity and mortality in psychotic depressive disorder: preliminary findings,” Psychoneuroendocrinology, vol. 33, no. 5, pp. 654–658, 2008. View at: Publisher Site | Google Scholar
  19. I. Kyrou and C. Tsigos, “Stress mechanisms and metabolic complications,” Hormone and Metabolic Research, vol. 39, no. 6, pp. 430–438, 2007. View at: Publisher Site | Google Scholar
  20. A. J. Lusis, “Atherosclerosis,” Nature, vol. 407, no. 6801, pp. 233–241, 2000. View at: Google Scholar
  21. G. K. Hansson, A. K. Robertson, and C. Soderberg-Naucler, “Inflammation and atherosclerosis,” Annual Review of Pathology, vol. 1, pp. 297–329, 2006. View at: Google Scholar
  22. G. Fricchione, R. Daly, M. P. Rogers, and G. B. Stefano, “Neuroimmunologic influences in neuropsychiatric and psychophysiologic disorders,” Acta Pharmacologica Sinica, vol. 22, no. 7, pp. 577–587, 2001. View at: Google Scholar
  23. C. L. Raison, L. Capuron, and A. H. Miller, “Cytokines sing the blues: inflammation and the pathogenesis of depression,” Trends in Immunology, vol. 27, no. 1, pp. 24–31, 2006. View at: Publisher Site | Google Scholar
  24. H. Nawa and N. Takei, “Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines,” Neuroscience Research, vol. 56, no. 1, pp. 2–13, 2006. View at: Publisher Site | Google Scholar
  25. E. Brietzke and F. Kapczinski, “TNF-alpha as a molecular target in bipolar disorder,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 6, pp. 1355–1361, 2008. View at: Publisher Site | Google Scholar
  26. N. Muller and M. J. Schwarz, “COX-2 inhibition in schizophrenia and major depression,” Current Pharmaceutical Design, vol. 14, no. 14, pp. 1452–1465, 2008. View at: Publisher Site | Google Scholar
  27. B. B. Simen, C. H. Duman, A. A. Simen, and R. S. Duman, “TNFα signaling in depression and anxiety: behavioral consequences of individual receptor targeting,” Biological Psychiatry, vol. 59, no. 9, pp. 775–785, 2006. View at: Publisher Site | Google Scholar
  28. R. Mössner and K.-P. Lesch, “Role of serotonin in the immune system and in neuroimmune interactions,” Brain, Behavior, and Immunity, vol. 12, no. 4, pp. 249–271, 1998. View at: Publisher Site | Google Scholar
  29. K. Schröcksnadel, B. Wirleitner, C. Winkler, and D. Fuchs, “Monitoring tryptophan metabolism in chronic immune activation,” Clinica Chimica Acta, vol. 364, no. 1-2, pp. 82–90, 2006. View at: Publisher Site | Google Scholar
  30. N. Muller and M. J. Schwarz, “The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression,” Molecular Psychiatry, vol. 12, no. 11, pp. 988–1000, 2007. View at: Publisher Site | Google Scholar
  31. M. Kubera et al., “Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6,” Psychiatry Research, vol. 134, no. 3, pp. 251–258, 2005. View at: Google Scholar
  32. J. Stefulj, B. Jernej, L. Cicin-Sain, I. Rinner, and K. Schauenstein, “mRNA expression of serotonin receptors in cells of the immune tissues of the rat,” Brain, Behavior, and Immunity, vol. 14, no. 3, pp. 219–224, 2000. View at: Publisher Site | Google Scholar
  33. B. Yu et al., “Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency,” Journal of Pharmacology and Experimental Therapeutics, vol. 327, no. 2, pp. 316–323, 2008. View at: Google Scholar
  34. I. Lucki, “The spectrum of behaviors influenced by serotonin,” Biological Psychiatry, vol. 44, no. 3, pp. 151–162, 1998. View at: Publisher Site | Google Scholar
  35. M. A. Geyer and F. X. Vollenweider, “Serotonin research: contributions to understanding psychoses,” Trends in Pharmacological Sciences, vol. 29, no. 9, pp. 445–453, 2008. View at: Publisher Site | Google Scholar
  36. A. Halaris, “Comorbidity between depression and cardiovascular disease,” International Angiology, vol. 28, no. 2, pp. 92–99, 2009. View at: Google Scholar
  37. O. M. E. Abdel-Salam, A. R. Baiuomy, and M. S. Arbid, “Studies on the anti-inflammatory effect of fluoxetine in the rat,” Pharmacological Research, vol. 49, no. 2, pp. 119–131, 2004. View at: Publisher Site | Google Scholar
  38. M. Bianchi, P. Sacerdot, and A. E. Panerai, “Fluoxetine reduces inflammatory edema in the rat: involvement of the pituitary-adrenal axis,” European Journal of Pharmacology, vol. 263, no. 1-2, pp. 81–84, 1994. View at: Google Scholar
  39. Z. Xia, J. W. DePierre, and L. Nassberger, “Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells,” Immunopharmacology, vol. 34, no. 1, pp. 27–37, 1996. View at: Google Scholar
  40. M. Kubera, G. Kenis, E. Bosmans et al., “Stimulatory effect of antidepressants on the production of IL-6,” International Immunopharmacology, vol. 4, no. 2, pp. 185–192, 2004. View at: Publisher Site | Google Scholar
  41. V. L. Serebruany, A. H. Glassman, A. I. Malinin et al., “Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the sertraline antidepressant heart attack randomized trial (SADHART) platelet substudy,” Circulation, vol. 108, no. 8, pp. 939–944, 2003. View at: Publisher Site | Google Scholar
  42. J. P. van Melle, H. Buikema, M. P. van Den Berg et al., “Sertraline causes strong coronary vasodilation: possible relevance for cardioprotection by selective serotonin reuptake inhibitors,” Cardiovascular Drugs and Therapy, vol. 18, no. 6, pp. 441–447, 2004. View at: Publisher Site | Google Scholar
  43. S. Ramamoorthy, J. D. Ramamoorthy, P. D. Prasad et al., “Regulation of the human serotonin transporter by interleukin-beta,” Biochemical and Biophysical Research Communications, vol. 216, no. 2, pp. 560–567, 1995. View at: Publisher Site | Google Scholar
  44. R. Mössner, A. Heils, G. Stöber, O. Okladnova, S. Daniel, and K.-P. Lesch, “Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6,” Neurochemistry International, vol. 33, no. 3, pp. 251–254, 1998. View at: Publisher Site | Google Scholar
  45. C.-B. Zhu, R. D. Blakely, and W. A. Hewlett, “The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters,” Neuropsychopharmacology, vol. 31, no. 10, pp. 2121–2131, 2006. View at: Publisher Site | Google Scholar
  46. R. Mössner et al., “Modulation of serotonin transporter function by interleukin-4,” Life Science, vol. 68, no. 8, pp. 873–880, 2001. View at: Google Scholar
  47. K. F. Foley et al., “IFN-gamma and TNF-alpha decrease serotonin transporter function and expression in Caco2 cells,” American Journal of Physiology, vol. 292, no. 3, pp. G779–G784, 2007. View at: Google Scholar
  48. D. E. Nichols and C. D. Nichols, “Serotonin receptors,” Chemical Reviews, vol. 108, no. 5, pp. 1614–1641, 2008. View at: Publisher Site | Google Scholar
  49. G. V. Williams, S. G. Rao, and P. S. Goldman-Rakic, “The physiological role of 5-HT2A receptors in working memory,” Journal of Neuroscience, vol. 22, no. 7, pp. 2843–2854, 2002. View at: Google Scholar
  50. D. E. Nichols, “Hallucinogens,” Pharmacology & Therapeutics, vol. 101, no. 2, p. 131, 2004. View at: Google Scholar
  51. F. X. Vollenweider, M. F. I. Vollenweider-Scherpenhuyzen, A. Bäbler, H. Vogel, and D. Hell, “Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action,” NeuroReport, vol. 9, no. 17, pp. 3897–3902, 1998. View at: Google Scholar
  52. G. K. Aghajanian and G. J. Marek, “Serotonin model of schizophrenia: emerging role of glutamate mechanisms,” Brain Research Reviews, vol. 31, no. 2-3, pp. 302–312, 2000. View at: Publisher Site | Google Scholar
  53. R. C. Shelton, E. Sanders-Bush, D. H. Manier, and D. A. Lewis, “Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A,” Neuroscience, vol. 158, no. 4, pp. 1406–1415, 2009. View at: Publisher Site | Google Scholar
  54. Z. Bhagwagar, R. Hinz, M. Taylor, S. Fancy, P. Cowen, and P. Grasby, “Increased 5-HT2A receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [11C]MDL 100,907,” American Journal of Psychiatry, vol. 163, no. 9, pp. 1580–1587, 2006. View at: Publisher Site | Google Scholar
  55. G. N. Pandey, Y. Dwivedi, H. S. Rizavi et al., “Higher expression of serotonin 5-HT2A receptors in the postmortem brains of teenage suicide victims,” American Journal of Psychiatry, vol. 159, no. 3, pp. 419–429, 2002. View at: Publisher Site | Google Scholar
  56. M. A. Oquendo, S. A. Russo, M. D. Underwood et al., “Higher postmortem prefrontal 5-HT2A receptor binding correlates with lifetime aggression in suicide,” Biological Psychiatry, vol. 59, no. 3, pp. 235–243, 2006. View at: Publisher Site | Google Scholar
  57. M. A. Mintun, Y. I. Sheline, S. M. Moerlein, A. G. Vlassenko, Y. Huang, and A. Z. Snyder, “Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography,” Biological Psychiatry, vol. 55, no. 3, pp. 217–224, 2004. View at: Publisher Site | Google Scholar
  58. T. Nagatomo et al., “Functions of 5-HT2A receptor and its antagonists in the cardiovascular system,” Pharmacology & Therapeutics, vol. 104, no. 1, pp. 59–81, 2004. View at: Google Scholar
  59. T. Brattelid et al., “Serotonin responsiveness through 5-HT2A and 5-HT4 receptors is differentially regulated in hypertrophic and failing rat cardiac ventricle,” Journal of Molecular and Cellular Cardiology, vol. 43, no. 6, pp. 767–779, 2007. View at: Google Scholar
  60. C. M. McKune and S. W. Watts, “Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling,” Journal of Pharmacology and Experimental Therapeutics, vol. 297, no. 1, pp. 88–95, 2001. View at: Google Scholar
  61. M.-A. Comet, J. F. Bernard, M. Hamon, R. Laguzzi, and C. Sévoz-Couche, “Activation of nucleus tractus solitarius 5-HT2A but not other 5-HT2 receptor subtypes inhibits the sympathetic activity in rats,” European Journal of Neuroscience, vol. 26, no. 2, pp. 345–354, 2007. View at: Publisher Site | Google Scholar
  62. D. N. Tu et al., “Blockade of the human ether-a-go-go-related gene potassium channel by ketanserin,” Sheng Li Xue Bao, vol. 60, no. 4, pp. 525–534, 2008. View at: Google Scholar
  63. Q. Tang et al., “The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-a-go-go-related gene (hERG) potassium channels,” British Journal of Pharmacology, vol. 155, no. 3, pp. 365–373, 2008. View at: Google Scholar
  64. J. M. Ju et al., “Ketanserin, a 5-HT2 antagonist, directly inhibits the ATP-sensitive potassium channel in mouse ventricular myocytes,” Journal of Cardiovascular Pharmacology, vol. 47, no. 1, pp. 96–102, 2006. View at: Google Scholar
  65. C. M. Villalón and D. Centurión, “Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 376, no. 1-2, pp. 45–63, 2007. View at: Google Scholar
  66. F. Orallo, H. Tristan, T. Garcia-Ferreiro et al., “Study of the in vivo and in vitro cardiovascular effects of four new analogues of ketanserin: implication of 5-HT(2A) and alpha1 adrenergic antagonism in their hypotensive effect,” Biological and Pharmaceutical Bulletin, vol. 23, no. 5, pp. 558–565, 2000. View at: Google Scholar
  67. P. A. van Zwieten, G. J. Blauw, and P. van Brummelen, “Serotonergic receptors and drugs in hypertension,” Pharmacology & Toxicology, vol. 70, no. 6, part 2, pp. S17–S22, 1992. View at: Google Scholar
  68. B. R. Teegarden, H. Al Shamma, and Y. Xiong, “5-HT2A inverse-agonists for the treatment of insomnia,” Current Topics in Medicinal Chemistry, vol. 8, no. 11, pp. 969–976, 2008. View at: Publisher Site | Google Scholar
  69. K. E. Vanover, D. Robbins-Weilert, D. G. Wilbraham et al., “Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers,” Journal of Clinical Pharmacology, vol. 47, no. 6, pp. 704–714, 2007. View at: Publisher Site | Google Scholar
  70. J. Diaz et al., “5-Hydroxytryptamine lowers blood pressure in normotensive and hypertensive rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 325, no. 3, pp. 1031–1038, 2008. View at: Google Scholar
  71. S. W. Watts, “The beginning of a fantastic, unanswered question: is 5-HT involved in systemic hypertension?” American Journal of Physiology, vol. 295, no. 3, pp. H915–H916, 2008. View at: Publisher Site | Google Scholar
  72. H. Isbell, “Comparison of the reactions induced by psilocybin and LSD-25 in man,” Psychopharmacologia, vol. 1, pp. 29–38, 1959. View at: Google Scholar
  73. R. R. Griffiths, W. A. Richards, U. McCann, and R. Jesse, “Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance,” Psychopharmacology, vol. 187, no. 3, pp. 268–283, 2006. View at: Publisher Site | Google Scholar
  74. F. Hasler, U. Grimberg, M. A. Benz, T. Huber, and F. X. Vollenweider, “Acute psychological and physiological affects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study,” Psychopharmacology, vol. 172, no. 2, pp. 145–156, 2004. View at: Publisher Site | Google Scholar
  75. R. J. Strassman and C. R. Qualls, “Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects,” Archives of General Psychiatry, vol. 51, no. 2, pp. 85–97, 1994. View at: Google Scholar
  76. R. R. Griffiths, W. A. Richards, M. W. Johnson, U. D. McCann, and R. Jesse, “Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later,” Journal of Psychopharmacology, vol. 22, no. 6, pp. 621–632, 2008. View at: Publisher Site | Google Scholar
  77. H. Y. Meltzer and M. Huang, “In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems,” Progress in Brain Research, vol. 172, pp. 177–197, 2008. View at: Publisher Site | Google Scholar
  78. J. W. Newcomer, “Antipsychotic medications: metabolic and cardiovascular risk,” Journal of Clinical Psychiatry, vol. 68, no. 68, supplement 4, pp. 8–13, 2007. View at: Google Scholar
  79. G. P. Reynolds, M. J. Hill, and S. L. Kirk, “The 5-HT2C receptor and antipsychoticinduced weight gain-mechanisms and genetics,” Journal of Psychopharmacology, vol. 20, supplement 4, pp. 15–18, 2006. View at: Google Scholar
  80. L. H. Tecott, L. M. Sun, S. F. Akana et al., “Eating disorder and epilepsy in mice lacking 5-HT(2C) serotonin receptors,” Nature, vol. 374, no. 6522, pp. 542–546, 1995. View at: Google Scholar
  81. D. D. Lam, M. J. Przydzial, S. H. Ridley et al., “Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors,” Endocrinology, vol. 149, no. 3, pp. 1323–1328, 2008. View at: Publisher Site | Google Scholar
  82. Y. Sugimoto and J. Yamada, “Effects of the 5-HT2A receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) on plasma glucose and glucagon levels of rats,” Biological and Pharmaceutical Bulletin, vol. 23, no. 12, pp. 1521–1523, 2000. View at: Google Scholar
  83. Y. Sugimoto et al., “The effects of peripheral serotonin2 (5-HT2) and serotonin3 (5-HT3) receptor agonists on blood glucose levels in rats,” Biological and Pharmaceutical Bulletin, vol. 19, no. 10, pp. 1384–1386, 1996. View at: Google Scholar
  84. M. Gilles et al., “Antagonism of the serotonin (5-HT)-2 receptor and insulin sensitivity: implications for atypical antipsychotics,” Psychosomatic Medicine, vol. 67, no. 5, pp. 748–751, 2005. View at: Google Scholar
  85. N. Kokubu, K. Tsuchihashi, S. Yuda et al., “Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease,” Circulation Journal, vol. 70, no. 11, pp. 1451–1456, 2006. View at: Publisher Site | Google Scholar
  86. M. Briley and C. Moret, “Neurobiological mechanisms involved in antidepressant therapies,” Clinical Neuropharmacology, vol. 16, no. 5, pp. 387–400, 1993. View at: Google Scholar
  87. S. Hjorth, H. J. Bengtsson, A. Kullberg, D. Carlzon, H. Peilot, and S. B. Auerbach, “Serotonin autoreceptor function and antidepressant drug action,” Journal of Psychopharmacology, vol. 14, no. 2, pp. 177–185, 2000. View at: Google Scholar
  88. J. A. Gray and B. L. Roth, “Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists,” Brain Research Bulletin, vol. 56, no. 5, p. 441, 2001. View at: Google Scholar
  89. E. Qvigstad, I. Sjaastad, T. Brattelid et al., “Dual serotonergic regulation of ventricular contractile force through 5-HT2A and 5-HT4 receptors induced in the acute failing heart,” Circulation Research, vol. 97, no. 3, pp. 268–276, 2005. View at: Publisher Site | Google Scholar
  90. R. L. Myers, D. C. Airey, D. H. Manier, R. C. Shelton, and E. Sanders-Bush, “Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression,” Biological Psychiatry, vol. 61, no. 2, pp. 167–173, 2007. View at: Publisher Site | Google Scholar
  91. D. Benmessaoud et al., “Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics,” BMC Psychiatry, vol. 8, article 40, 2008. View at: Google Scholar
  92. M. J. Choi et al., “Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram,” Neuropsychobiology, vol. 52, no. 3, pp. 155–162, 2005. View at: Google Scholar
  93. M. J. Choi et al., “Association between major depressive disorder and the -1438A/G polymorphism of the serotonin 2A receptor gene,” Neuropsychobiology, vol. 49, no. 1, pp. 38–41, 2004. View at: Google Scholar
  94. I.-S. Chee, S. W. Lee, J. L. Kim et al., “5-HT2A receptor gene promoter polymorphism -1438A/G and bipolar disorder,” Psychiatric Genetics, vol. 11, no. 3, pp. 111–114, 2001. View at: Publisher Site | Google Scholar
  95. E. M. Peñas-Lledó, P. Dorado, M. C. Cáceres, A. de La Rubia, and A. Llerena, “Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs,” Clinical Chemistry and Laboratory Medicine, vol. 45, no. 7, pp. 835–838, 2007. View at: Publisher Site | Google Scholar
  96. P. A. Sáiz, M. P. García-Portilla, C. Arango et al., “Association study of serotonin 2A receptor (5-HT2A) and serotonin transporter (5-HTT) gene polymorphisms with schizophrenia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 31, no. 3, pp. 741–745, 2007. View at: Publisher Site | Google Scholar
  97. Y. Suwazono et al., “The -1438A/G polymorphism in the 5-hydroxytryptamine receptor 2A gene is related to hyperuricemia, increased gamma-glutamyl transpeptidase and decreased high-density lipoprotein cholesterol level in the Japanese population: a prospective cohort study over 5 years,” International Journal of Molecular Medicine, vol. 17, no. 1, pp. 77–82, 2006. View at: Google Scholar
  98. A. Kling et al., “Genetic variations in the serotonin 5-HT2A receptor gene (HTR2A) are associated with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 67, no. 8, pp. 1111–1115, 2008. View at: Google Scholar
  99. J. H. Choi et al., “The association between the T102C polymorphism of the HTR2A serotonin receptor gene and HDL cholesterol level in Koreans,” Journal of Biochemistry and Molecular Biology, vol. 38, no. 2, pp. 238–242, 2005. View at: Google Scholar
  100. B.-N. Yu, A. Wang, G. Zhou et al., “T102C genetic polymorphism of the 5-HT2A receptor in Chinese hypertensive patients and healthy controls,” Clinical and Experimental Pharmacology and Physiology, vol. 31, no. 12, pp. 847–849, 2004. View at: Publisher Site | Google Scholar
  101. S. Yamada et al., “T102C polymorphism of the serotonin (5-HT) 2A receptor gene in patients with non-fatal acute myocardial infarction,” Atherosclerosis, vol. 150, no. 1, pp. 143–148, 2000. View at: Google Scholar
  102. I. Halder et al., “Serotonin receptor 2A (HTR2A) gene polymorphisms are associated with blood pressure, central adiposity, and the metabolic syndrome,” Metabolic Syndrome and Related Disorders, vol. 5, no. 4, pp. 323–330, 2007. View at: Google Scholar
  103. L. Salomon, C. Lanteri, G. Godeheu, G. Blanc, J. Gingrich, and J.-P. Tassin, “Paradoxical constitutive behavioral sensitization to amphetamine in mice lacking 5-HT2A receptors,” Psychopharmacology, vol. 194, no. 1, pp. 11–20, 2007. View at: Publisher Site | Google Scholar
  104. N. V. Weisstaub, M. Zhou, A. Lira et al., “Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice,” Science, vol. 313, no. 5786, pp. 536–540, 2006. View at: Publisher Site | Google Scholar
  105. D. Popa, C. Léna, V. Fabre et al., “Contribution of 5-HT2 receptor subtypes to sleep-wakefulness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors,” Journal of Neuroscience, vol. 25, no. 49, pp. 11231–11238, 2005. View at: Publisher Site | Google Scholar

Copyright © 2009 Charles D. Nichols. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.